Browse
Submit Data
Databases
API
Help

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Different Training methods on Accuracy of Predicting Conlorectal Lesions and Selection of Interventions by trainees: multicenter, randomized, controlled trial

ABSTRACT: Interventions: Gold Standard:Pathological examination; Senior endoscope doctor;Index test:Primary endoscope doctor by different training methods Primary outcome(s): NPV Study Design: Parallel

DISEASE(S): Colorectal Tumors

PROVIDER: 2692245 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Multiple-trait genomic selection methods increase genetic value prediction accuracy.

Project description: Not available

| S-EPMC3512156 | biostudies-literature

Project description:Senior sportsmen

| PRJNA723822 | ENA

Excavation and clinical verification of early warning biomarkers for hand-foot syndrome induced by capecitabine

Project description:Interventions: Gold Standard:Clinical outcome;Index test:Study on endogenous biomarkers by targeted metabonomics Primary outcome(s): SEN, SPE, ACC, AUC of ROC, PPV, NPV Study Design: Sequential

| 2698756 | ecrin-mdr-crc

Multifactorial Approach to Predicting Resistance to Anthracyclines

Project description:PURPOSE: Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant TOP trial, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase IIα (TOP2A) and to develop a gene expression signature to identify those patients who do not benefit from anthracyclines. METHODS: The TOP trial included 149 patients, of which 141 were evaluable for response prediction analyses. The primary endpoint was pathological complete response (pCR). TOP2A and gene expression profiles were evaluated using pre-epirubicin biopsies. Gene expression data from ER-negative samples of the EORTC 10994/BIG 00-01 and MDACC 2003-0321 neoadjuvant trials were used for validation purposes. RESULTS: A pCR was obtained in 14% of the evaluable TOP patients. TOP2A amplification, but not protein overexpression, was significantly associated with pCR (p=0.001 and 0.22). We developed an “anthracycline-based score (A-Score)” that combines three signatures: a TOP2A gene signature and two previously published signatures related to tumor invasion and immune response. The A-Score was characterized by a high negative predictive value (NPV=0.98 [95% CI: 0.90-1.00]) overall, and in the HER2-negative and HER2-positive subpopulations. Its performance was independently confirmed in the anthracycline-based (FAC/FEC) arms of the two validation trials (BIG 00-01: 0.80 [0.61-0.92] and MDACC 2003-0321: 1.00 [0.80-1.00]). CONCLUSION: Given its high NPV, the A-Score could become, if further validated, a useful clinical tool to identify those patients who do not benefit from anthracyclines and could therefore be spared the non-negligible side effects.

2010-01-26 | GSE16446 | GEO

Establishment of prognostic prediction model for left and right colon cancer based on AI technology

Project description:Interventions: Gold Standard:Clinical outcome;Index test:Prognostic prediction model for left and right colon cancer based on AI technology Primary outcome(s): tumor stroma ratio;immunescore;SEN, SPE, ACC, AUC of ROC, PPV, NPV Study Design: Sequential

| 2697591 | ecrin-mdr-crc

Methods of tagSNP selection and other variables affecting imputation accuracy in swine.

Project description: Not available

| S-EPMC3734000 | biostudies-literature

Descriptor selection for predicting interfacial thermal resistance by machine learning methods.

Project description: Not available

| S-EPMC7804206 | biostudies-literature

Establishment and validation of therapeutic effect prediction model of first line treatment of bevacizumab combined with mFOLFOX6 in Ras mutant colorectal cancer patients with liver metastasis

Project description:Interventions: Gold Standard:Clinical outcome;Index test:Therapeutic effect prediction model of first line treatment of bevacizumab combined with mFOLFOX6 in Ras mutant colorectal cancer patients with liver metastasis Primary outcome(s): Objective response rate;SEN, SPE, ACC, AUC of ROC, PPV, NPV Study Design: Sequential

| 2696954 | ecrin-mdr-crc

Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation.

Project description: Not available

| S-EPMC7865009 | biostudies-literature

Assessing the accuracy and stability of variable selection methods for random forest modeling in ecology.

Project description: Not available

| S-EPMC6049094 | biostudies-literature